Pharmaceutical research has generated a string of breakthrough drugs, saving millions of lives and drastically improving quality of life. Ongoing research promises more innovation in the next decade. But miracle drugs raise difficult issues in pricing, especially in developing nations.
Drug manufacturers charge much lower prices in developing nations but worry about transshipment to rich countries. Poor nations are using the World Trade Organization negotiation process to seek the right to manufacture or import generic versions of patented drugs. These events could blunt research incentives.
At this event, experts will address questions such as: What are new drugs really worth? What is coming out of research labs, and is pharmaceutical research and development slowing down? How are breakthrough drugs priced abroad? How should they be priced, without sacrificing research incentives?
